

Study of serum hepcidin level and its relation to recombinant human erythropoietin resistance, markers of iron status and C-reactive protein in patients with end stage renal disease on maintenance hemodialysis.

Ayman M. Elbadawy, W. M. Ibraheim, Medhat A. Khalil, Omar N. Elhawary,
Rasha O. Abdelmoniem.

Internal Medicine Department, Faculty of Medicine, Benha University, Egypt.

Abstract

Background: Anemia represents a significant problem to deal with in patients with chronic kidney disease (CKD) on hemodialysis (HD). This work aimed to determine the usefulness of measuring serum hepcidin level in patients with end stage renal disease (ESRD) on maintenance hemodialysis and anemia, and assess the possible correlation between serum hepcidin level and markers of iron status (serum iron, serum ferritin, total iron binding capacity and iron saturation), erythropoietin resistance and inflammatory markers (C-reactive protein). **Methods:** The study was performed on (50 patients) with end stage renal disease on maintenance hemodialysis. Patients were divided into two groups: group (I): 40 patients who have anemia responsive to erythropoietin therapy and group (II): 10 patients who have anemia resistant to erythropoietin therapy. All patients were subjected to thorough history taking, clinical examination, and laboratory investigations as complete blood count (CBC), serum hepcidin level, markers of iron status (Serum iron, serum ferritin, total iron binding capacity, and transferrin saturation), C-reactive protein (CRP), serum parathormone hormone level (PTH), total and ionized calcium (Ca⁺⁺), serum phosphorus (Po⁴⁻), serum creatinine, blood urea, hepatitis B surface antigen (HBsAg) and hepatitis C antibody. **Results:** serum hepcidin level was higher in all patients with erythropoietin resistance index (ERI) > 15 compared to patients with ERI < 15. There was a highly significant positive correlation between serum hepcidin level and ERI and significant negative correlation between serum hepcidin level and serum iron, ferritin and transferrin saturation. But no significant correlation was found between serum hepcidin level and C-reactive protein. **Conclusion:** Hpcidin is associated with anemia, markers of iron status and erythropoietin resistance. If used as a diagnostic tool, it might improve iron therapy in patients with functional iron deficiency due to reticuloendothelial blockage of iron transport. This is important to avoid iron overload and to improve erythropoietin (EPO) response in patients with ESRD.

Keywords : Hpcidin; Erythropoietin resistance; Markers of iron status; Inflammatory markers.

Introduction

Chronic kidney disease (CKD) is defined as the presence of kidney damage or an estimated glomerular filtration rate (eGFR) less than 60 ml/min/1.73 mt², persisting for 3 months or more, irrespective of the cause. It is a state of progressive loss of kidney function ultimately resulting in the need for renal replacement therapy (dialysis or transplantation). (1)

Anemia is a common comorbidity associated with chronic kidney disease (CKD); it starts early in the course of the disease and worsens as renal function declines, Anemia associated with declining kidney function is predominantly due to inadequate renal production of the hormone erythropoietin in response to low hemoglobin (Hb) levels. As kidney function worsens, erythropoietin production decreases, resulting in the frequent comorbidity of anemia with CKD. (2)

Hepcidin, an endogenous peptide secreted by the liver, has been identified as controlling the level of plasma iron by regulating the intestinal absorption of dietary iron, as well as the release of iron from macrophages and the transfer of iron stored in the hepatocytes. Hepcidin production is suppressed in the case of iron deficiency; the feedback loop between iron and hepcidin should ensure the appropriate physiological concentration of iron in the plasma. Hepcidin suppression causes the stored iron to be released by hepatocytes and macrophages while the intestinal absorption of iron increases. (3)

Hepcidin is elevated during inflammation and/or infection. This can cause iron dysregulation with hypoferremia and anemia related to inflammatory disease, Hypoferremia can also represent a strategic host defense to limit iron availability to microorganisms. Kidney function (i.e., excretion) plays an important role in hepcidin clearance. Patients with end stage renal disease on maintenance hemodialysis have decreased levels of hepcidin clearance and hepcidin level increases regardless of the inflammatory state. (4)

This study aimed to determine the usefulness of measuring serum hepcidin level in patients with end stage renal disease on maintenance hemodialysis and anemia, and to assess the possible correlation between serum hepcidin level and markers of iron status (serum iron, serum ferritin, TIBC and iron saturation), erythropoietin resistance, and inflammatory markers as CRP.

Patients and methods

This cross-sectional study was conducted on 50 patients attending the Dialysis unit at benha health insurance hospital during the period from January 2020 to January 2021.

The study was performed on (50 patients) with end stage renal disease on maintenance hemodialysis. Patients were divided into two groups: group (I): 40 patients who have anemia responsive to erythropoietin therapy and group (II): 10 patients who have anemia resistant to erythropoietin therapy.

All patients had been informed about the purpose of the study and signed consent before inclusion.

Inclusion criteria:

1. patients with end stage renal disease (ESRD) on maintenance hemodialysis, with good patient compliance and less missed treatments.
2. Age 18–75 years old.
3. Patients receiving recombinant erythropoietin therapy for at least 8 week for treatment of anemia.

Patients who fulfilled the inclusion criteria were on regular dialysis three sessions per week, 4 h for each session using 'Fresenius 4008S Classic' dialysis machine at blood flow rate of 300–350 ml/min, dialysate flow rate of 600 ml/min, using high flux polysulfone hollow fiber dialyzers suitable for the surface area of the patients (Fresenius FX8=1.4 m², FX10=1.8 m² and F6=1.2 m²) with adequate dialysis treatment ($Kt/V > 1.4$) in more than 80% of the patients.

Exclusion criteria:

Patients were excluded from the study if they had :

- Uncontrolled hypertension or diabetes.
- Liver dysfunction.
- Malignancy.
- Hemoglobinopathies.
- Hepatitis C or Hepatitis B virus.
- Active or subclinical infection.
- Blood transfusion within the past 3 months.
- Patients treated with steroids or other immunosuppressive drugs are also excluded from the study.

All patients were subjected to thorough history taking, clinical examination, and laboratory investigations as complete blood count (CBC), serum hepcidin level, markers of iron status (Serum iron, serum ferritin, total iron binding capacity, and transferrin saturation), C-reactive protein (CRP), serum parathormone hormone level (PTH), total and ionized calcium (Ca⁺⁺), serum phosphorus (Po⁴⁻), serum creatinine, blood urea, hepatitis B surface antigen (HBsAg) and hepatitis C antibody.

The erythropoietin resistance index (ERI) was calculated as the weekly dose of EPO (IU/kg/week) divided by hemoglobin concentration (g/dl) multiplied by the dry body weight (Kg) of each patient (where the dry weight was the postdialysis body weight averaged across 3 dialysis sessions at the end of the outcome period).

Serum hepcidin was measured using enzyme-linked immunosorbent assay. The assay was carried out by hepcidin enzyme-linked immunosorbent assay kits.

Statistical analysis:

The collected data were tabulated and analyzed using SPSS version 16 soft ware (SpssInc, Chicago, ILL Company). Categorical data were presented as number and percentages, Fisher's exact tests was used to analyze them. Quantitative data were tested for normality using Shapiro -Wilks test assuming normality at $P > 0.05$. Normally distributed variables were expressed as mean \pm standard deviation, median was added if non parametric. Student "t" test was used to analyze the difference between 2 independent groups regarding parametric variables, while non parametric ones were analyzed by Mann Whitney U test (Z_{MWU}). Correlation was assessed by the non-parametric correlation coefficient Spearman (rho).

Multiple linear regression analysis was run to detect the predictors of Hepcidin and ERI. ROC curve was constructed to determine a cutoff value of Hepcidin and assess its performance in prediction of erythropoietin resistance among dialysis patients. $P \leq 0.05$ was considered significant.

Results


Patients had an age range between 18 and 75 years old with a mean of 52.3 ± 14.5 years. Regarding sex of the patients, 41 patients (82 %) were males and 9 (18 %) were females. The mean body mass index (BMI) was 27.4 ± 3.7 kg/m². (**Table 1**)

Table (1): Socio-demographic data of the studied group:

Variable		No. (N=50)	
Age (years)	Mean \pm SD	52.3 \pm 14.5	
	Median (Range)	57 (20-74)	
Sex (n., %)	Male	41	82.0
	Female	9	18.0
Weight (kg)	Mean \pm SD	79.8 \pm 13.5	
	Median (Range)	81 (61-120)	
BMI (kg/m ²)	Mean \pm SD	27.4 \pm 3.7	
	Median (Range)	27.3 (19.4-37)	

BMI: body mass index.

We divided our patients into EPO sensitive and EPO resistant groups according to the erythropoietin resistant index (ERI). We found that 80 % of patients were EPO sensitive (40 patients) with ERI < 15 and 20 % were EPO resistant (10 patients) with EPO > 15. (**Figure 1**)



(Fig 1) : Bar chart showing the frequency of EPO resistance among the studied sample.

(**Table 2**) shows the comparison between the EPO sensitive patients and the EPO resistant patients according to different laboratory results. There was statistically significant difference between groups regarding serum hepcidin level, Hb, iron, TIBC, ferritin, and transferrin saturation. Whereas there was no statistically significant difference between groups regarding mean CRP level, PTH, total calcium, or phosphorus.

(**Table 3**) shows the correlation between serum hepcidin level and different variables. There was a significant positive correlation between hepcidin and (ESA/w, TIBC, phosphorus, and ERI), and a significant negative correlation between hepcidin and (Hb level, iron level, ferritin, and T.saturation). No significant correlation between hepcidin and (age, weight, BMI, CRP titre, PTH, or serum ca) was found.

(**Table 4**) shows Correlation between erythropoietin resistance index and the studied variables. There was a significant positive correlation between ERI and (ESA/w, TIBC, and hepcidin level), and a significant negative correlation between ERI and (Hb level, iron level, ferritin, and transferrin saturation). While there was no significant correlation between ERI and (age, weight, BMI, CRP, PTH, total Ca, or phosphorus).

Table (2): Comparison between EPO sensitive and resistant patients regarding different laboratory parameters :

Variable	Erythropoietin sensitive (n=40)			Erythropoietin resistant (n=10)			Z _{MWU}	P
	Mean	± SD	Median (Range)	Mean	± SD	Median (Range)		
Hb (g/dl)	11.0	0.84	11.1 (9.2-12.2)	10.1	0.65	10.3 (9.4-11)	2.87	0.004 (S)
Serum iron (ug/dl)	74.8	28.6	66.0 (37-146)	62.6	20.0	49.0 (17-85)	2.55	0.011 (S)
TIBC (ug/dl)	257.6	39.1	258.0 (208-338)	316.0	91.2	272.0 (269-489)	2.16	0.031 (S)
Serum ferritin (ng/ml)	648.5	633.9	627.0 (49-3055)	305.5	211.1	207.5 (129-647)	2.43	0.015 (S)
Transferrin saturation (%)	28.4	11.90	24.9 (7.6-53)	19.7	8.58	18.0 (10-31.6)	2.1	0.036 (S)
Serum PTH (pg/ml)	456.7	330.4	353.0 (24-1062)	422.6	288.2	312.0 (213-960)	0.097	0.92 (NS)
Total ca (mg/dl)	8.47	0.90	8.8 (7.2-10.3)	8.66	0.58	8.6 (7.9-9.6)	0.27	0.78 (NS)
Serum phosphorus (mg/dl)	5.64	1.34	5.7 (2.5-8.3)	5.90	1.25	5.9 (4.3-7.5)	0.53	0.59 (NS)
Serum hepcidin (ng/ml)	736.3	603.3	462.3 (29.8-1780)	1298.1	598.1	1632.0 (203.3-1782)	2.24	0.025 (S)
CRP titer (mg/L)	29.6	25.5	20 (6-96)	32.2	31	24 (6-96)	0.18	0.85 (NS)

Hb: hemoglobin; TIBC: Total Iron Binding Capacity; PTH: Serum Parathormone hormone level; Ca: Calcium (Ca⁺⁺)

Table (3): Correlation between serum hepcidin level and different variables :

With	Hepcidin (ng/ml)	
	Dialysis patients (N=50)	
	rho	P
Age (ys)	0.017	0.91
Weight (Kg)	0.033	0.82
BMI (Kg/m ²)	0.223	0.11
ESA/ w	0.504	<0.001 (HS)
Hb (g/dl)	-0.328	0.02 (S)
CRP titre (mg/L) (n=32)	0.279	0.12
Iron (ug/dl)	-0.394	0.005 (S)
TIBC (ug/dl)	0.280	0.049 (S)
Ferritin (ng/ml)	-0.300	0.034 (S)
Transferrin saturation (%)	-0.380	0.006 (S)
PTH (pg/ml)	0.158	0.27
Total ca (mg/dl)	0.01	0.95
Phosphorus (mg/dl)	0.407	0.003 (S)
ERI	0.462	=0.001 (HS)

ESA: erythropoiesis-stimulating agents; BMI: body mass index; CRP: C-reactive protein; Hb: hemoglobin; TIBC: Total Iron Binding Capacity; PTH: Serum Parathormone hormone level; Ca: Calcium (Ca⁺⁺); ERI: Erythropoietin resistant index

(Table 4) : Correlation between erythropoietin resistance index and the studied variables :

With	ERI	
	Dialysis patients (N=50)	
	rho	P
Age (ys)	0.076	0.59
Weight (Kg)	0.193	0.18
BMI (Kg/m ²)	0.269	0.059
ESA/ w	0.907	<0.001 (HS)
Hb (g/dl)	-0.570	<0.001 (HS)
CRP titre (mg/L) (n=32)	0.064	0.73
Iron (ug/dl)	-0.415	0.003 (S)
TIBC (ug/dl)	0.331	0.019 (S)
Ferritin (ng/ml)	-0.441	=0.001 (HS)
Transferrin saturation (%)	-0.466	=0.001 (HS)
PTH (pg/ml)	0.128	0.37
Total ca (mg/dl)	-0.190	0.18
Phosphorus (mg/dl)	0.215	0.13
Hepcidin (ng/ml)	0.462	=0.001 (HS)

Discussion

Anemia is a common complication in hemodialysis (HD) patients. Despite the great success of erythropoietin therapy in clinical practice, resistance to this therapy is common. In this study, we have assessed 50 end stage renal disease patients on maintenance hemodialysis and suffering from anemia treated with erythropoietin therapy.

Patients with CKD who have resistance to erythropoietin therapy have an increased cardiovascular morbidity and all-cause mortality. Erythropoietin therapy are known to improve the quality of life and also decrease the demand of blood transfusion. (5)

Our study aimed to quantify serum hepcidin levels in hemodialysis patients so as to establish the linkage between hepcidin and hemoglobin, markers of iron status, CRP and eventually to resolve its involvement with EPO resistance.

We calculated erythropoietin resistance index (ERI) with the equation: Mean ESA dose (units/week)/(dry weight [kg] × mean Hgb [g/dL]), and found that 80 % of patients were EPO sensitive (40 patients) with $ERI > 15$ and 20 % were EPO resistant (10 patients) with $ERI < 15$.

We found that there is a highly significant positive correlation between serum hepcidin level and ERI among our hemodialysis patients . This correlation is due to the effect of hepcidin on iron as hepcidin decreases available iron and hence decreases erythropoiesis and hemoglobin concentration, so that patients with decreased hemoglobin will get higher doses of EPO per week.

According to the equation of ERI, ERI is directly proportional to the weekly doses of EPO but inversely proportional to mean hemoglobin level so higher hepcidin will lead to more high ERI and this can explain our study results and also in agreement with Petruļienė et al. study results. (5)

However, other authors present opposite results. For Example Costa et al. (6) and do someiro-faira et al. (7) studies found that hepcidin serum levels among EPO resistant group ($ERI > 15$) were significantly lower than among EPO sensitive group ($ERI < 15$).

As EPO resistant group present with higher inflammatory markers, hepcidin levels are expected to be increased, but it has been demonstrated that erythropoietin down-regulates liver hepcidin expression, acting, therefore, as a hepcidin inhibitory hormone. Since EPO resistant group were treated with much higher doses of erythropoietin compared with EPO sensitive group, the lower hepcidin levels among EPO resistant group could be explained by this mechanism.

In our study, we found that Hb level was higher in EPO sensitive group compared to the lower Hb level in EPO resistant group and we also found that serum hepcidin level is higher in EPO resistant group compared to the lower levels in EPO sensitive group. Our results showed a significant negative correlation between serum hepcidin level and hemoglobin concentration.

In normal healthy individual, the decrease in Hb level will have a negative feedback inhibition on hepcidin that will allow more iron to be available for erythropoiesis, But in CKD patient there is an impairment in hepcidin clearance through kidneys that allow hepcidin to build up in blood and cause reticuloendothelial block, decrease iron availability and eventually worsening of anemia. This may explain the significant negative correlation that we have found in our study.

Our results are in agreement with Rubab et al. (8) and Petruilienė et al. (5) that found significantly higher hepcidin and lower Hb levels in EPO resistant hemodialysis patients. This also matched with El-HadyAhmed et al. (9) and Shinzato et al. (10), both of them were done on similar sample size like our study.

We found that serum iron level is elevated in EPO sensitive group compared to lower iron level in EPO resistant group. There was a significant negative correlation between serum hepcidin level and serum iron. In agreement with our results, El-HadyAhmed et al. (9) and Kadery Alkemyary et al. (11) showed that there is a significant negative correlation between hepcidin and serum iron. But in contrast to our results, Rubab et al. (8) found no correlation between serum hepcidin and iron levels.

We found that serum ferritin level is higher in EPO sensitive group compared to the lower serum ferritin level in EPO resistant group.

In our study there was a significant negative correlation between serum hepcidin and serum ferritin levels. This may be explained by the higher target of serum ferritin level need to be reached in hemodialysis patient than in normal healthy population and the maintenance intravenous iron given on weekly basis to overcome iron loss during each dialysis session that allow iron availability and suppress hepcidin production in those patients.

Serum ferritin is a marker of iron stores in the liver and reticuloendothelial system (RES) as well as being an acute phase protein, So the high ferritin level in hemodialysis patients couldn't be fully explained by inflammation and need further evaluation.

Our results were in agreement to Kadery Alkemyary et al. (11) that found a significant negative correlation between serum hepcidin levels and ferritin. This was in contrast to Al-Amir et al. (12), El-

HadyAhmed et al. (9), Kato et al. (13) and Tomosugi et al. (14) that found a highly significant positive correlation between serum hepcidin levels and ferritin. This may be explained by the higher sample size than our study and that Al-Amir et al. (12) was done on hemodialysis patients with chronic hepatitis C virus .

Otherwise, Elmenyawy et al. (15) found there was insignificant positive weak correlations between serum levels of hepcidin and ferritin. The variable study results may be explained by the diurnal variation in serum hepcidin concentration that was not found in ferritin measurement and that the influence of inflammation on hepcidin in hemodialysis patients is not crucial and other factors (eg : hepcidin retention due to renal impairment) are involved.

We found that transferrin saturation is higher in EPO sensitive group compared to the lower saturation in EPO resistant group. there was a significant negative correlation between serum hepcidin level and transferrin saturation. This correlation is due to the blocking effect of hepcidin on reticuloendothelial system that decreases iron availability and therefore decreases transferrin saturation .

Our results are consistent with Petruilienè et al. (5), But in contrast to Goyal et al. (16) that found significant positive correlation between serum hepcidin and transferrin saturation. As this study was done in CKD 3-5 non dialysis patients that could be explained by stopping the EPO therapy two weeks before the study, the larger sample size compared to our study and the younger age group chosen for their study. This difference between results in dialysis versus non-dialysis patients can explain the effect of hemodialysis on removal of hepcidin.

We found that CRP titer is higher in EPO resistant group with compared to lower levels in EPO sensitive group. As it is known that hepcidin synthesis is induced by inflammation, so positive correlation between hepcidin and CRP was very expected especially among patients undergoing hemodialysis which is currently being considered as an inflammatory state. However, We found that there is no significant correlation between serum hepcidin and CRP titer in our study.

Our results were in agreement with Petruilienè et al. (5) that also found no apparent correlation between CRP and hepcidin. Unlike our study, Ford et al. (17), Rubab et al. (8) and Ibrahim et al. (18) showed that there is a significant positive correlation of hepcidin levels with CRP. This may possibly be due to exclusion of patients with active infection and may be explained on the basis of differences in the half-lives of CRP and hepcidin and the diurnal variation of hepcidin.

We found that all patients in the EPO resistant group required treatment with higher doses of EPO compared to the lower doses required in most of EPO sensitive group. There was a highly significant positive

correlation between serum hepcidin level and the weekly dose of EPO in our hemodialysis patients.

This correlation is due to the hepcidin blocking effect on reticuloendothelial system that decrease iron availability and hence decrease erythropoiesis and hemoglobin concentration so patients will require more doses of EPO to suppress the effect of hepcidin.

As erythropoietin (EPO) is the primary signal that triggers erythropoiesis in anemic and hypoxic conditions, so Pinto et al. (19) studied the effect of Erythropoietin dose on hepcidin regulation and reported that EPO has a direct dose-dependant role in the regulation of hepcidin expression.

This is in agreement with Sezgin and Zumrutdal (20) which reported that the hepcidin levels in hemodialysis patients who received no EPO were lower when compared with the levels in those patients and receiving the maximum dose of EPO .

This also matched with Takasawa et al. (21) that was done on hemodialysis patients and showed that the short and long-acting EPO exert biphasic effects on hepcidin in early upregulation followed by late downregulation. An early rise in serum hepcidin in response to EPO may be dependent on serum ferritin and predictive of the response to EPO in hemodialysis patients.

But unlike our finding, Afifi et al. (22) found no significant correlation between hepcidin and dose of erythropoietin in hemodialysis patients. And Ibrahim et al. (18) found that there was a significant negative correlation between serum hepcidin levels and weekly Erythropoietin doses .

The different study results could be explained by understanding that the dose of erythropoietin is not the only factor that regulate hepcidin level and additional mediators of hepcidin expression in the context of erythropoiesis, has recently been demonstrated for the TGF- β super-family member GDF15. And so that a direct signaling of EPO to the hepatocyte could be one of the mechanisms underlying the reported in vivo hepcidin modulation by erythropoiesis. (19)

We found that serum PTH was higher in EPO sensitive group compared to the lower level in the EPO resistant group. Excessive parathormone levels are known to reduce EPO production, increase hemolysis, and suppress stem cells of the red blood cell line in the bone marrow. As a result it will increase the EPO dose required for those patients that will eventually suppress hepcidin production. (23)

In contrast to that, we found that there is no significant correlation between serum hepcidin level and serum PTH in our hemodialysis

patients. This is consistent with Petruilienè et al. (5) and Ibrahim et al. (18) studies that found no possible correlation between serum hepcidin and serum PTH. But Unlike our finding, Hyang Ki Min, Su Ah Sung (24) that was done on non-dialysis patients, found that there is a significant positive correlation between hepcidin and PTH.

We also found that serum phosphorous is higher in EPO resistant group compared to lower level in EPO sensitive group. There was a significant positive correlation between serum hepcidin level and serum phosphorous in our hemodialysis patients. This correlation could be due to the effect of decreased renal clearance of both hepcidin and phosphorous. This was in agreement with Zaritsky et al. (25) and Hyang Ki Min, Su Ah Sung (24) studies that showed a significant positive correlation between hepcidin and phosphorous level in hemodialysis patients.

In contrast to our results, Petruilienè et al. (5) and Ibrahim et al. (18) studies found no possible correlation between serum hepcidin and serum phosphorous in hemodialysis patients.

We found that serum total calcium is higher in EPO resistant group compared to the lower level in EPO sensitive group. There is no significant correlation between serum hepcidin level and serum total calcium. This is consistent with Petruilienè et al. (5) but unlike our finding, Ibrahim et al. (18) study showed a significant positive correlation between serum hepcidin level and serum total calcium.

These variations in results could be explained by the different types of hyperparathyroidism (either the patient has secondary or tertiary hyperparathyroidism) and the different mechanisms of actions of treatment regimens like Vitamin D (that suppresses PTH but increases phosphorous and calcium) and calcimimetics (that suppress PTH, phosphorous and calcium) and phosphorous lowering agents (Calcium based or non-calcium based medications).

In addition, As phosphorous needs more time to be cleared during hemodialysis session and its clearance depends on the adequacy of dialysis (Kt/v), so the variation in results also may be explained according to the different dialyzers used in hemodialysis units (high flux vs low flux dialyzer) and the duration of dialysis session .

We found that patients in the EPO resistant group had higher BMI compared to patients in the EPO sensitive group. There was no significant correlation between serum hepcidin level and BMI. In contrast with our results, Tussing-Humphreys et al. (26) showed a positive correlation between serum hepcidin levels and BMI; however, in our HD patients this correlation is not found, suggesting that the adipose tissue has no impact on the circulating levels of hepcidin.

These results enforce evidence from studies demonstrating that obesity in HD patients seems to play a protective role. Tanner et al. (27), Kalantar-Zadeh K et al. (28) and Kalaitzidis & Siamopoulos (29). But According to Kittiskulnam et al. (30) BMI is not a reliable indicator of adiposity because it does not differentiate between subcutaneous fat, visceral fat, or muscle. This problem can be exacerbated in disease states such as ESRD treated by hemodialysis, in which muscle may account for a smaller percentage of body weight because of wasting or edema.

We found that patients in the EPO resistant group were older compared to patients in the EPO sensitive group. There was no significant correlation between serum hepcidin level and the age of our hemodialysis patients. In agreement with our findings, Ibrahim et al. (18) demonstrated that there was no statistically significant correlation between hepcidin and patient age. This is in contrast to Al-Amir et al. (12) that found a statistically significant positive correlation between age and hepcidin levels among hemodialysis patients.

Given the limited number and size of studies to date, the unresolved issues surrounding hepcidin assays themselves, and the numerous factors that can modulate hepcidin levels in the CKD/ESRD population including iron administration, ESA administration, body iron stores, inflammation, renal clearance, and dialysis adequacy, more studies will be needed to determine whether hepcidin will have diagnostic utility as a measure of iron status, inflammatory status, and/or ESA responsiveness or resistance.

Conclusion

Hepcidin is associated with anemia, markers of iron status and erythropoietin resistance. If used as a diagnostic tool, it might improve iron therapy in patients with functional iron deficiency due to reticuloendothelial blockage of iron transport. This is important to avoid iron overload and to improve erythropoietin (EPO) response in patients with ESRD. In addition to that, these findings may be of great benefit to understand the importance of hepcidin antagonists to treat anemia in hemodialysis patients.

Sources of funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Author contribution

Authors contributed equally in the study.

Conflicts of interest

No conflicts of interest

References

1. Vaidya SR, Aeddula NR. Chronic Renal Failure. In: StatPearls [Internet]. StatPearls Publishing; 2019.
2. Shaikh H, Aeddula NR. Anemia of chronic renal disease. StatPearls [Internet]. 2020;
3. D'angelo G. Role of hepcidin in the pathophysiology and diagnosis of anemia. *Blood Res.* 2013;48(1):10–5.
4. Suega K, Widiana GR. Predicting hepcidin level using inflammation markers and iron indicators in patients with anemia of chronic disease. *Hematol Transfus cell Ther.* 2019;41(4):342–8.
5. Petrulienė K, Žiginskienė E, Kuzminskis V, Nedzelskienė I, Bumblytė IA. Hepcidin serum levels and resistance to recombinant human erythropoietin therapy in hemodialysis patients. *Med* [Internet]. 2017 Jan 1 [cited 2020 Aug 7];53(2):90–100. Available from: <https://pubmed.ncbi.nlm.nih.gov/28416170/>
6. Costa E, Swinkels DW, Laarakkers CM, Rocha-Pereira P, Rocha S, Reis F, et al. Hepcidin Serum Levels and Resistance to Recombinant Human Erythropoietin Therapy in Haemodialysis Patients. *Acta Haematol* [Internet]. 2009 [cited 2020 Aug 7];122(4):226–9. Available from: <https://www.karger.com/Article/FullText/253590>
7. Do Sameiro-Faria M, Ribeiro S, Rocha-Pereira P, Fernandes J, Reis F, Bronze-Da-Rocha E, et al. Body mass index and resistance to recombinant human erythropoietin therapy in maintenance hemodialysis patients. *Ren Fail* [Internet]. 2013 Nov [cited 2020 Aug 8];35(10):1392–8. Available from: <https://pubmed.ncbi.nlm.nih.gov/23991655/>
8. Rubab Z, Amin H, Abbas K, Hussain S, Ullah MI kra., Mohsin S. Serum hepcidin levels in patients with end-stage renal disease on hemodialysis. *Saudi J Kidney Dis Transpl* [Internet]. 2015 Jan 1 [cited 2020 Aug 7];26(1):19–25. Available from: <http://www.sjkdt.org/article.asp?issn=1319-2442;year=2015;volume=26;issue=1;spage=19;epage=25;aulast=Rubab>
9. El-HadyAhmed H, Emam El-Maghraby A, El-Hady Ahmed H. EVALUATION OF THE ROLE OF HEPCIDIN IN PREDICTING THE THERAPEUTIC EFFICACY OF ERYTHROPOIESIS-STIMULATING AGENT TREATMENT IN PATIENTS OF CHRONIC RENAL FAILURE [Internet]. Vol. 22, ZUMJ. 2016 [cited 2020 Aug 12]. Available from: www.zumed.zu.edu.eg
10. Shinzato T, Abe K, Furusu A, Harada T, Shinzato K, Miyazaki M, et al. Serum pro-hepcidin level and iron homeostasis in Japanese dialysis patients with erythropoietin (EPO)-resistant anemia. *Med Sci Monit* [Internet]. 2008 Sep 1 [cited 2020 Aug 12];14(9):CR431-7. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/18758412>
11. Kadery Alkmary A, Elgarem N, Taha Mohamed R, Ismail Aboueleinein B. OF ADVANCED RESEARCH Value of hepcidin in diagnosis and monitoring of iron disorders in patients on regular hemodialysis and its relation to hev infection. *Int J Adv Res* [Internet]. 2016 [cited 2020 Aug 14];4(7):1651–62. Available from: www.eiaab.com

12. Al-Amir M, Hassan A, Elshafie S, Zein Elabdin H, Taha S. The relationship between anemia, serum hepcidin levels, and chronic hepatitis C in chronic hemodialysis patients. *Egypt J Intern Med* [Internet]. 2017 [cited 2020 Jun 18];29(3):112. Available from: <http://www.esim.eg.net/text.asp?2017/29/3/112/214798>
13. Kato A, Tsuji T, Luo J, Sakao Y, Yasuda H, Hishida A. Association of prohepcidin and hepcidin-25 with erythropoietin response and ferritin in hemodialysis patients. *Am J Nephrol* [Internet]. 2007 Nov [cited 2020 Aug 14];28(1):115–21. Available from: <https://pubmed.ncbi.nlm.nih.gov/17943020/>
14. Tomosugi N, Kawabata H, Wakatabe R, Higuchi M, Yamaya H, Umehara H, et al. Detection of serum hepcidin in renal failure and inflammation by using ProteinChip System. *Blood* [Internet]. 2006 Aug 15 [cited 2020 Aug 14];108(4):1381–7. Available from: <https://pubmed.ncbi.nlm.nih.gov/16621968/>
15. Elmenyawi AAI, Hassan A, Said SA. Relationship between Hepcidin, Ferritin and C-Reactive Protein in Hemodialysis Patients. *Egypt J Hosp Med*. 2017 Oct;69(2):1786–93.
16. Goyal H, Mohanty S, Sharma M, Rani A. Study of anemia in nondialysis dependent chronic kidney disease with special reference to serum hepcidin. *Indian J Nephrol*. 2017 Jan 1;27(1):44–50.
17. Ford BA, Eby CS, Scott MG, Coyne DW. Intra-individual variability in serum hepcidin precludes its use as a marker of iron status in hemodialysis patients. *Kidney Int* [Internet]. 2010 Oct 2 [cited 2020 Aug 14];78(8):769–73. Available from: <http://www.kidney-international.org>
18. Ibrahim I, Mohamad U, Rashad A, Darweesh H. Impact of hepcidin, interleukin 6, and other inflammatory markers with respect to erythropoietin on anemia in chronic hemodialysis patients. *Egypt J Intern Med* [Internet]. 2014 [cited 2020 Aug 14];26(1):6. Available from: <http://www.esim.eg.net/text.asp?2014/26/1/6/132882>
19. Pinto JP, Ribeiro S, Pontes H, Thowfeequ S, Tosh D, Carvalho F, et al. Erythropoietin mediates hepcidin expression in hepatocytes through EPOR signaling and regulation of C/EBP α . *Blood* [Internet]. 2008 Jun 15 [cited 2020 Aug 12];111(12):5727–33. Available from: </pmc/articles/PMC2597200/?report=abstract>
20. Zumrutdal A, Sezgin N. The relationship between anemia, liver disease, and hepcidin levels in hemodialysis patients with hepatitis. *Indian J Nephrol* [Internet]. 2012 Nov [cited 2020 Jun 18];22(6):415. Available from: <http://www.indianjnephrol.org/text.asp?2012/22/6/415/106031>
21. Takasawa K, Tomosugi N, Takaeda C, Maeda T, Ueda N. Regulation of Hepcidin-25 by Short- and Long-Acting rhEPO May Be Dependent on Ferritin and Predict the Response to rhEPO in Hemodialysis Patients. *Nephron Extra* [Internet]. 2014 Apr 16 [cited 2020 Aug 12];4(1):55–63. Available from: </pmc/articles/PMC4024510/?report=abstract>
22. Afifi W, Mostafa E, Elsaid M, Elakad G, Ebian H. Serum hepcidin levels and erythropoietin resistance in hemodialysis patients. *J Egypt Soc Nephrol Transplant* [Internet]. 2019 [cited 2020 Aug 8];19(1):13. Available from: <http://www.jesnt.eg.net/text.asp?2019/19/1/13/255244>

23. Tanaka M, Komaba H, Fukagawa M. Emerging Association Between Parathyroid Hormone and Anemia in Hemodialysis Patients. Vol. 22, Therapeutic Apheresis and Dialysis. Blackwell Publishing Ltd; 2018. p. 242–5.
24. Hyang Ki Min, Su Ah Sung YKO et al. Hepcidin, iron indices and bone mineral metabolism in non-dialysis chronic kidney disease | Nephrology Dialysis Transplantation | Oxford Academic [Internet]. Oxford University Press. 2018 [cited 2020 Aug 8]. p. 147–154. Available from: <https://academic.oup.com/ndt/article-abstract/35/1/147/5057655?redirectedFrom=fulltext>
25. Zaritsky J, Young B, Gales B, Wang HJ, Rastogi A, Westerman M, et al. Reduction of serum hepcidin by hemodialysis in pediatric and adult patients. Clin J Am Soc Nephrol [Internet]. 2010 Jun 1 [cited 2020 Aug 12];5(6):1010–4. Available from: </pmc/articles/PMC2879302/?report=abstract>
26. Tussing-Humphreys LM, Nemeth E, Fantuzzi G, Freels S, Guzman G, Holterman AXL, et al. Elevated systemic hepcidin and iron depletion in obese premenopausal females. Obesity [Internet]. 2010 Jul [cited 2020 Aug 8];18(7):1449–56. Available from: <https://pubmed.ncbi.nlm.nih.gov/19816411/>
27. Tanner RM, Brown TM, Muntner P. Epidemiology of obesity, the metabolic syndrome, and chronic kidney disease. Curr Hypertens Rep [Internet]. 2012 Apr [cited 2020 Aug 8];14(2):152–9. Available from: <https://pubmed.ncbi.nlm.nih.gov/22318504/>
28. Kalantar-Zadeh K, Abbott KC, Salahudeen AK, Kilpatrick RD, Horwich TB. Survival advantages of obesity in dialysis patients. Am J Clin Nutr [Internet]. 2005 Mar 1 [cited 2021 Feb 15];81(3):543–54. Available from: <https://academic.oup.com/ajcn/article/81/3/543/4648877>
29. Kalaitzidis RG, Siamopoulos KC. The role of obesity in kidney disease: recent findings and potential mechanisms. NEPHROLOGY-REVIEW. 2011;
30. Kittiskulnam P, Chertow GM, Kaysen GA, Delgado C, Dalrymple LS, Johansen KL. Misclassification of obesity by body mass index among patients receiving hemodialysis [Internet]. Vol. 67, American Journal of Kidney Diseases. W.B. Saunders; 2016 [cited 2020 Aug 14]. p. 709–11. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5657149/>